AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
GETI-B.ST
ACCE-researched

Getinge AB (publ) (GETI-B.ST) fair value

Healthcare · Medical Devices · Nasdaq Stockholm · Sweden
kr 267.70+0.64%
Market cap kr 72.9BNext earnings 2026-10-21Updated Oct 23, 2026
Our verdict
Trades 25% above our fair value
Price
kr 267.70
Model fair valueConfidence: good
kr 214
Model range
kr 137 to kr 329
Fair value kr 214
Price kr 268
4 models fit Getinge AB (publ) and they disagree: 1 of 4 land within 15% of the average.
Two or more of our models back this value.
Premium(i)Silver61
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionGetinge AB (publ) (GETI-B.ST)
Fair value (4 models)
kr 214
ACCE price target
kr 258
Rating
Overvalued
Horizon
12 months
Fair value published on 22 Oct 2026, 12:04 CEST.
ACCE price target published on 22 Oct 2026, 16:00 CEST.
Rating published on 22 Oct 2026, 12:04 CEST.
Price used: kr 268 at the close on 23 Oct 2026, 17:30 CEST.
Models: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
25.3% above
-20.2% to fair value
ACCE score
65
out of 100
P/E
25.8x
forward 24.5x
1-year return
+19.0%
Dividend yield
1.79%

Getinge AB (publ) in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Getinge makes surgical tables, operating room lights, sterilizers and the Maquet and Datascope lines of cardiovascular and critical-care equipment, selling them into hospital operating theatres and intensive care units worldwide. Its moat rests on installed base and service contracts: once a hospital has standardised on Getinge sterilization and OR infrastructure, replacement and recurring servicing are sticky, which supports a 48.6% gross margin. Organic revenue growth has been muted, at 1.7% over the latest period, so the investment case depends on margin recovery and cost discipline rather than top-line acceleration. At a trailing P/E of 25.6 and a forward P/E of 24.3, the market is already paying a premium for a business earning a 16.1% operating margin and an 8.9% return on equity, so the stock needs the margin trajectory to hold or improve to justify a deeper look.

AI-assisted·How I use AIWritten Oct 23, 2026
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
  • moderate
    Revenue growth stalled
    Revenue grew only 1.7% year on year and the 5-year revenue CAGR is 3.2%, so top-line growth is slow for a medical devices name.
  • moderate
    Price well above model fair value
    The stock trades 25.3% above the model fair value of kr 213.61, leaving less room for error if earnings growth slows.

AI research notes

AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Free cash flow over the last twelve months reached SEK 2.6B, showing the business still turns sales into real cash.
  • Net margin of 7.8% and the latest earnings beat of +52.8% suggest profitability is improving faster than the sales line.
  • The share trades at 18.1x forward earnings against a sector median of 25.2x, a meaningful discount to peers.
Why it could disappoint
  • The stock trades 25.3% above the model fair value of kr 213.61, so the price already assumes more than the models support.
  • Return on invested capital of 4.6% sits well below what a healthy medical equipment maker would normally earn on the money it uses.
  • Revenue grew only +1.7% year over year, slower than the +3.2% five-year average, so the top line is losing momentum.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where GETI-B.ST's valuation models land
Price
kr 267.70
Model fair value
kr 214
Model range
kr 137 to kr 329
Fair value kr 214
Price kr 268
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Recent performance

1 week
+2.3%
1 month
+8.9%
3 months
+16.2%
6 months
+39.4%
YTD
+22.3%
1 year
+19.0%

Recommendation history, last 12 months

DateTypeNewPreviousPrice
22 Oct 2026, 16:00 CESTACCE price targetkr 258first publicationkr 260
22 Oct 2026, 12:04 CESTRatingOvervaluedfirst publicationkr 260
22 Oct 2026, 12:04 CESTFair valuekr 212first publicationkr 260

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

This security trades in SEK. Exchange-rate movements can increase or reduce the result in your own currency.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full GETI-B.ST page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth47Value58Quality63Momentum90Total65
Valuation
Trailing P/E
25.8x
Forward P/E
24.5x
PEG
0.95
P/B
2.16x
EV / Revenue
2.2x
Book value/sh
kr 119.88
Enterprise value
kr 76.0B
Profitability
ROE
9.1%
FCF yield
3.62%
ROIC
4.6%
Health and risk
Debt / equity
0.37
Dividend yield
1.79%
Beta
0.82

Price

+20.2% · 1Y

Ask anything about GETI-B.ST

Answered from Getinge AB (publ) fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 25.8x25.8xhigh 104.4x
ROEbetter than 83% of peers
low -9%9%high 28%
Div yieldbetter than 67% of peers
low 0.0%1.8%high 2.0%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
GETI-B.ST Getinge AB (publ)kr 267.70kr 21425% above25.8x9.1%6365
6869.T Sysmex Corporation¥1965.00--30.8x8.3%6773
COH.AX Cochlear LimitedA$140.59A$7978% above62.5x8.0%7144
SECT-B.ST Sectra AB (publ)kr 334.80kr 95253% above104.4x28.3%8568
BRKR Bruker Corporation Common Stock$57.31----3.0%4352
TXG 10x Genomics Inc. Class A Common Stock$69.75----9.4%4742
BIO Bio-Rad Laboratories Inc. Class A Common Stock$363.50$27632% above45.7x3.1%6255

Sector report card

Where GETI-B.ST ranks against its sector peers on each metric.

Computing percentiles…